JP2025508882A5 - - Google Patents

Info

Publication number
JP2025508882A5
JP2025508882A5 JP2024550728A JP2024550728A JP2025508882A5 JP 2025508882 A5 JP2025508882 A5 JP 2025508882A5 JP 2024550728 A JP2024550728 A JP 2024550728A JP 2024550728 A JP2024550728 A JP 2024550728A JP 2025508882 A5 JP2025508882 A5 JP 2025508882A5
Authority
JP
Japan
Prior art keywords
seq
cytokine
domain
mutation
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024550728A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025508882A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/014128 external-priority patent/WO2023164288A2/en
Publication of JP2025508882A publication Critical patent/JP2025508882A/ja
Publication of JP2025508882A5 publication Critical patent/JP2025508882A5/ja
Pending legal-status Critical Current

Links

JP2024550728A 2022-02-28 2023-02-28 標的化サイトカインおよびその使用方法 Pending JP2025508882A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263314926P 2022-02-28 2022-02-28
US202263314928P 2022-02-28 2022-02-28
US63/314,926 2022-02-28
US63/314,928 2022-02-28
PCT/US2023/014128 WO2023164288A2 (en) 2022-02-28 2023-02-28 Targeted cytokines and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2025508882A JP2025508882A (ja) 2025-04-10
JP2025508882A5 true JP2025508882A5 (cg-RX-API-DMAC7.html) 2026-03-05

Family

ID=85791876

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024550728A Pending JP2025508882A (ja) 2022-02-28 2023-02-28 標的化サイトカインおよびその使用方法

Country Status (11)

Country Link
US (1) US20230365641A1 (cg-RX-API-DMAC7.html)
EP (1) EP4486460A2 (cg-RX-API-DMAC7.html)
JP (1) JP2025508882A (cg-RX-API-DMAC7.html)
KR (1) KR20240152853A (cg-RX-API-DMAC7.html)
CN (1) CN120248131A (cg-RX-API-DMAC7.html)
AU (1) AU2023225803A1 (cg-RX-API-DMAC7.html)
CA (1) CA3247112A1 (cg-RX-API-DMAC7.html)
IL (1) IL314922A (cg-RX-API-DMAC7.html)
MX (1) MX2024010488A (cg-RX-API-DMAC7.html)
TW (1) TW202342504A (cg-RX-API-DMAC7.html)
WO (1) WO2023164288A2 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3217029A1 (en) 2021-05-30 2022-12-08 Biolojic Design Ltd. Engineered dual binding antibodies and uses thereof
CN116554344A (zh) * 2022-01-30 2023-08-08 中国科学院生物物理研究所 一种pd1抗体与白介素2融合的双功能分子
IL326617A (en) * 2023-08-30 2026-04-01 Xilio Dev Inc Masked il-2 cytokines and methods of use thereof
EP4770754A1 (en) * 2023-08-30 2026-07-08 Xilio Development, Inc. Vhh masked cytokines and methods of use thereof
WO2025151274A1 (en) * 2024-01-08 2025-07-17 Adimab, Llc Inducible il-18 prodrugs
WO2025151752A1 (en) * 2024-01-10 2025-07-17 Xilio Development, Inc. Masked il-2 cytokines and methods of use thereof
WO2025242836A1 (en) * 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of auto-immune or inflammatory diseases and disorders
WO2025242835A1 (en) * 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
CN113286812B (zh) * 2018-09-27 2025-05-30 西里欧发展公司 掩蔽型细胞因子多肽
EP4017594A1 (en) * 2019-08-21 2022-06-29 Askgene Pharma, Inc. Novel il-21 prodrugs and methods of use thereof
PH12022552627A1 (en) * 2020-04-01 2023-01-04 Xilio Dev Inc Masked il-2 cytokines and their cleavage products
PH12022552630A1 (en) * 2020-04-01 2023-01-04 Xilio Dev Inc Masked il-15 cytokines and their cleavage products
BR112022019708A2 (pt) * 2020-04-01 2022-12-20 Xilio Dev Inc Citocina il-12 mascarada, produtos de clivagem, ácidos nucleicos, vetor, célula hospedeira, composições, kit, método de produção de uma citocina il-12 mascarada e métodos de tratamento ou prevenção de câncer
EP4251187A4 (en) * 2020-11-25 2025-09-10 Xilio Dev Inc TUMOR-SPECIFIC CLASSIBLE LINKERS

Similar Documents

Publication Publication Date Title
JP7457764B2 (ja) ヘテロ二量体多重特異性抗体フォーマット
JP7579795B2 (ja) NKp30に結合する抗体分子およびその使用
JP6622396B2 (ja) 多重特異性抗体プラットフォームおよびその関連方法
TWI788286B (zh) 三特異性和/或三價結合蛋白
AU2012236603B2 (en) Dual variable region antibody-like binding proteins having cross-over binding region orientation
CN114901679A (zh) 全新被掩蔽的细胞因子及其应用
US12098203B2 (en) Hetero-dimeric multi-specific antibody format targeting at least CD3 and HSA
CA3151791A1 (en) Pd-1 targeted il-15/il-15ralpha fc fusion proteins with improved properties
US20230348593A1 (en) Antibody molecules that bind to nkp30 and uses thereof
JP2013515509A5 (cg-RX-API-DMAC7.html)
EP4017594A1 (en) Novel il-21 prodrugs and methods of use thereof
JP2025508316A5 (cg-RX-API-DMAC7.html)
CN105229036A (zh) 在疏水性相互作用位点内引入了静电相互作用的蛋白及其制备方法
JP2023550419A5 (cg-RX-API-DMAC7.html)
WO2020135804A1 (zh) 异源二聚体融合蛋白
CN119604525A (zh) 促进多特异性抗体的重链和轻链同源配对的突变体
JP2024516098A (ja) Bcmaを標的とする多重特異性抗体
JP2023553692A (ja) 標的治療のための前駆体タンパク質及びキット
WO2025092987A9 (zh) 基于Fc区的异二聚体分子及其用途
CN117586411A (zh) 一种结合tnfr2和ccr8的双特异性抗体
EA041608B1 (ru) Гетеродимерный полиспецифичный формат антител